

CANCER

The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17

Daniele Chaves-Moreira¹, Marilyn A. Mitchell¹, Cristina Arruza¹, Priyanka Rawat¹, Simone Sidoli^{2†}, Robbin Nameki^{3,4}, Jessica Reddy^{3,4}, Rosario I. Corona^{3,4}, Lena K. Afeyan^{5,6}, Isaac A. Klein^{5,7‡}, Sisi Ma⁸, Boris Winterhoff⁹, Gottfried E. Konecny¹⁰, Benjamin A. Garcia², Donita C. Brady^{11,12}, Kate Lawrenson^{3,13}, Patrice J. Morin¹, Ronny Drapkin^{1*}

Copyright © 2022
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim
to original U.S.
Government Works

PAX8 is a master transcription factor that is essential during embryogenesis and promotes neoplastic growth. It is expressed by the secretory cells lining the female reproductive tract, and its deletion during development results in atresia of reproductive tract organs. Nearly all ovarian carcinomas express PAX8, and its knockdown results in apoptosis of ovarian cancer cells. To explore the role of PAX8 in these tissues, we purified the PAX8 protein complex from nonmalignant fallopian tube cells and high-grade serous ovarian carcinoma cell lines. We found that PAX8 was a member of a large chromatin remodeling complex and preferentially interacted with SOX17, another developmental transcription factor. Depleting either PAX8 or SOX17 from cancer cells altered the expression of factors involved in angiogenesis and functionally disrupted tubule and capillary formation in cell culture and mouse models. PAX8 and SOX17 in ovarian cancer cells promoted the secretion of angiogenic factors by suppressing the expression of *SERPINE1*, which encodes a proteinase inhibitor with antiangiogenic effects. The findings reveal a non-cell-autonomous function of these transcription factors in regulating angiogenesis in ovarian cancer.

INTRODUCTION

Epithelial ovarian carcinoma (EOC) is the most lethal of all gynecologic malignancies, annually claiming an estimated 13,000 lives in the United States (1), with worldwide numbers approaching 180,000 deaths yearly (2, 3). The lack of effective screening tools results in the majority of cases being diagnosed at an advanced stage, translating into a 5-year survival rate of less than 30% (4). In addition, EOC has the propensity to acquire chemoresistance and to relapse in most patients, despite initial response to platinum-based chemotherapy after surgical cytoreduction. Although there has been much progress in our understanding of ovarian cancer at the molecular level, targeted therapies have yet to affect overall survival rates (5).

Our understanding of the pathogenesis of high-grade serous ovarian carcinoma (HGSOC), the most common subtype of EOC, has greatly advanced over the past decade. Numerous studies suggest that the fallopian tube secretory epithelial cell (FTSEC) is the cell of origin for the majority of HGSOC (6–15). The development of the fallopian tubes and the rest of the female reproductive tract is governed by the PAX8 transcription factor (16). PAX8 is a member of the Paired-Box (PAX) family of transcription factors that play essential roles during embryogenesis and tumorigenesis (17, 18). In normal fallopian tubes, PAX8 expression is restricted to the secretory cells; neighboring ciliated cells exhibit no expression. The sustained expression of PAX8 in adult FTSECs and nearly all HGSOCs (19) previously led us to use the PAX8 promoter to develop a genetically engineered mouse model of HGSOC (20, 21). Knockdown of PAX8 in ovarian cancer cells leads to apoptosis (22–24), supporting a critical role for PAX8 in ovarian cancer growth and progression. Unlike the negligible impact on gene expression in fallopian tube cell lines (24, 25), PAX8 loss in the cancer cell lines alters a considerably high number of transcripts associated with proliferation, angiogenesis, and adhesion pathways (25). Chromatin immunoprecipitation sequencing (ChIP-seq) analysis had shown that the PAX8 cisome is reprogrammed during the process of malignant transformation by the widespread redistribution of PAX8-binding sites in the genome of ovarian cancer cells. Moreover, noncoding somatic mutations disrupt the PAX8 transcriptional program in ovarian cancer (26).

To further define the roles of PAX8 in ovarian carcinomas, we purified the PAX8 protein complex from a panel of FTSECs and HGSOC cells, identified its components, and analyzed its biological role. Our findings indicate that PAX8 is part of a chromatin remodeling complex that critically involves SOX17 to promote angiogenesis. Our findings further suggest that targeting this pathway might be a viable therapeutic target in ovarian cancer.

¹Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Biomedical Research Building II/III, Suite 1224, Philadelphia, PA 19104, USA. ²Epigenetics Institute, Department of Biochemistry and Biophysics, Smilow Center for Translational Research, University of Pennsylvania Perelman School of Medicine, Suite 9-124, Philadelphia, PA 19104, USA. ³Women's Cancer Research Program at the Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. ⁴Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. ⁵Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA. ⁶Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. ⁷Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. ⁸Institute for Health Informatics, University of Minnesota, Minneapolis, MN 55455, USA. ⁹Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN 55455, USA. ¹⁰Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. ¹¹Department of Cancer Biology, University of Pennsylvania Perelman School of Medicine, Biomedical Research Building II/III, Suite 612, Philadelphia, PA 19104, USA. ¹²Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Biomedical Research Building II/III, Suite 612, Philadelphia, PA 19104, USA. ¹³Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

*Corresponding author. Email: rdrapkin@pennmedicine.upenn.edu

†Present address: Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

‡Present address: Dewpoint Therapeutics, Boston, MA 02210, USA.

RESULTS

Biochemical purification of the PAX8 complex

To better understand the function of PAX8 in malignant ovarian cancer cells and benign fallopian tube secretory cells, we developed a biochemical affinity purification method (Fig. 1A). First, we generated nuclear extracts as previously described (27) and purified the endogenous PAX8 protein complex from three ovarian carcinoma cell lines (OVCAR4, KURAMOCHI, and OVSAHO) and three immortalized FTSEC lines (FT194, FT246, and FT282) using PAX8-specific antibodies. Immunoblotting after affinity chromatography demonstrated the specific enrichment of PAX8 in our system

(Fig. 1B). When the affinity-purified PAX8 complex was evaluated on size exclusion chromatography, it revealed a size of approximately 600 kDa (Fig. 1C). Mass spectrometry (MS) analysis of the PAX8-containing fractions from the Sephacryl S-300 column identified several putative PAX8-interacting proteins in both normal and cancer cells. Several proteins were common to the PAX8 complexes from normal and cancer cells, with a subset of these proteins present at different levels in these cells (Fig. 1D and Table 1).

Many of the putative PAX8-interacting proteins represent components of chromatin remodeling complexes, including chromodomain-helicase-DNA binding protein 4 (CHD4), transcriptional repressor




Fig. 1. Three-step proteomic approach identifies putative PAX8-interacting partners. (A) Schematic of the workflow for the PAX8-interacting partner identification. (B) Representative examples of endogenous PAX8 immunoprecipitation from fallopian tube secretory cell line FT194 (lane "FT") and HGSOC line OVCAR4 (lane "OC") detected by silver staining and immunoblotting. IMR90 cells, which are PAX8 negative, were used as negative control (lane "C"). The arrow indicates migration of full-length PAX8. (C) Representative immunoblot of size exclusion fractions for PAX8 in OVCAR4 cells. (D) PAX8 immunoprecipitates and gel filtration fractions shown in (B) and (C) were analyzed by mass spectrometry to identify PAX8-interacting partners. The results are shown as a volcano plot, displayed as interacting proteins detected in greater amounts in isolates from fallopian tube cells than those from HGSOCs and vice versa. Plot shows averaged data from all three HGSOC cell lines (OVCAR4, KURAMOCHI, and OVSAHO) and all three fallopian tube cell lines (FT194, FT246, and FT282). (E) Assessment of PAX8 and SOX17 interaction by coimmunoprecipitation assay in lysates from FT194 (FT) and OVCAR4 (OC) cell lines. (F) Immunoblotting for PAX8 and SOX17 in size exclusion fractions to assess coelution in OVCAR4 cells. Blots in (B), (C), (E), and (F) show a representative of three OC and three FT cell lines independently assessed.

Table 1. Putative PAX8-interacting partners. Nuclear extracts from FT194, FT246, FT282, OVCAR4, KURAMOCHI, and OVSAHO cells were used for affinity purification of PAX8 before fractionation on a Sephacryl S-300 column. PAX8-enriched fractions from the column were subjected to mass spectrometry to identify PAX8-associated proteins.

UniProtKB accession no.	Spot name	Description	Theoretical mass (kDa)	MaxQuant search results			Log fold change Cancer versus normal*
				No. of matched peptides	Sequence coverage (%)	Score	
Transcription factors and regulators							
Q06710	PAX8	Paired box protein 8	48.2	13	33.8	162.9	+1.38
Q13263	TRIM28	Transcription intermediary factor 1-β	88.5	5	11.3	79.4	−0.22
Q1MSW8	TP53	Cellular tumor antigen p53	50.2	4	22.2	76.1	+2.79
Q9H6I2	SOX17	Transcription factor SOX17	44.3	3	11.1	74.8	+1.05
P78347	GTF2I	General transcription factor III	107.9	19	11.3	73.3	+1.06
Q86YP4	GATAD2A	Transcriptional repressor p66-alpha	68.1	7	9.6	45.1	−0.66
P40763	STAT3	Signal transducer and activator of transcription 3	76.1	8	3.9	39.6	+0.01
A5YKK6	CNOT1	CCR4-NOT transcription complex subunit 1	266.4	6	2.5	38.1	−1.13
P17480	UBTF	Nucleolar transcription factor 1	75.9	10	6.3	31.6	−0.96
P51532	SMARCA4	Transcription activator BRG1	184.6	15	3.9	28.8	−0.18
O00268	TAF4	Transcription initiation factor TFIID subunit 4	50.2	3	6.8	20.4	+0.70
O60885	BRD4	Bromodomain- containing protein 4	152.2	3	2.5	18.7	−2.08
Q13573	SNW1	SNW domain- containing protein 1	43.3	3	9.9	18.1	+1.57
O75448	MED24	Mediator of RNA polymerase II transcription subunit 24	91.3	3	4.6	17.8	−0.79
Q9NZN8	CNOT2	CCR4-NOT transcription complex subunit 2	29.9	2	9.1	16.7	−0.97
P20290	BTF3	Transcription factor BTF3	17.7	2	17.3	14.6	+2.02
A0A0U1RRM1	GATAD2B	Transcriptional repressor p66-β	63.4	4	5.9	14.2	−0.30
E9PJZ4	MED17	Mediator of RNA polymerase II transcription subunit 17	16.3	2	16.1	13.8	+1.94

continued on next page

UniProtKB accession no.	Spot name	Description	Theoretical mass (kDa)	MaxQuant search results			Log fold change Cancer versus normal*
				No. of matched peptides	Sequence coverage (%)	Score	
Q96EI5	TCEAL4	Transcription elongation factor A protein-like 4	21.5	5	11.8	12.5	0.00
H3BQQ2	ZNF598	Zinc finger protein 598	93.3	4	1.5	12.5	+0.34
Q9NYF8	BCLAF1	Bcl-2-associated transcription factor 1	52.9	11	5.4	12.2	−0.23
O75175	CNOT3	CCR4-NOT transcription complex subunit 3	31.2	8	16.3	10.9	−4.48
Q4FD37	ZNF148	Zinc finger protein 148	74.5	4	1.2	9.2	0.00
Q96AQ6	PBXIP1	Pre-B cell leukemia transcription factor-interacting protein 1	57.5	6	2.2	8.5	+0.65
P42224	STAT1	Signal transducer and activator of transcription 1-alpha/beta	88.3	3	1.7	8.1	−0.93
Q9ULX9	MAFF	Transcription factor MafF	14.5	2	11.9	7.5	0.00
Q13127	REST	RE1-silencing transcription factor	52.2	3	2.1	7.3	+1.02
P46937	YAP1	Transcriptional coactivator YAP1	18.7	9	6.5	6.6	+1.27
P53999	SUB1	Activated RNA polymerase II transcriptional coactivator p15	14.4	3	18.9	6.4	+1.90
P40424	PBX1	Pre-B cell leukemia transcription factor 1	46.6	1	10.3	5.8	+0.78
P18846	ATF1	Cyclic AMP- dependent transcription factor ATF-1	57.6	23	5.8	2.1	+0.03
RNA processing							
Q9BQ02	NCL	Nucleolin	76.6	11	30.1	188.9	−0.63
A8K849	ZFR	Zinc finger RNA binding protein	66.3	3	7.1	16.6	+0.41
Q9NVP1	DDX18	ATP-dependent RNA helicase DDX18	61.6	4	4.4	13.9	+2.24
Q59FS7	DDX24	ATP-dependent RNA helicase DDX24	75.1	1	1.6	8.4	+5.29
Q9Y2W2	WBP11	WW domain- binding protein 11	64.9	1	2.4	7.2	+0.93

continued on next page

UniProtKB accession no.	Spot name	Description	Theoretical mass (kDa)	MaxQuant search results			Log fold change Cancer versus normal*
				No. of matched peptides	Sequence coverage (%)	Score	
DNA processing							
P33993	MCM7	DNA replication licensing factor MCM7	81.2	11	23.8	114.6	+0.35
Q92878	RAD50	DNA repair protein RAD50	138.4	12	11.5	85.4	+0.49
Q9Y265	RUVBL1	RuvB-like 1	50.2	8	25.4	76.1	+1.46
Q14839	CHD4	Chromodomain- helicase-DNA binding protein 4	215.2	15	3.6	45.8	+0.18
Q9P258	RCC2	Protein RCC2	56.1	5	14.2	43.2	+1.53
Q9Y230	RUVBL2	RuvB-like 2	51.1	9	13.2	35.4	+0.84
P49736	MCM2	DNA replication licensing factor MCM2	87.4	6	6.1	26.2	−0.09
P18887	XRCC1	DNA repair protein XRCC1	42.8	2	5.8	13.5	−1.03
B7Z8C6	DBF4	Protein DBF4 homolog A	51.8	2	3.1	6.5	+1.75
Epigenetic regulators							
Q09028	RBBP4	Histone-binding protein RBBP4	46.9	4	7.9	27.9	−2.96
O94776	MTA2	Metastasis- associated protein 2	75.0	3	3	12.5	+0.03
Q6IT96	HDAC1	Histone deacetylase	55.1	2	4.4	11.8	+1.99
Q96L91	EP400	E1A-binding protein p400	335.8	1	0.6	9.4	+0.31
Q8TEK3	DOT1L	Histone lysine N- methyltransferase, H3 lysine-79 specific	24.1	3	3.4	7.6	−1.60
Q9UPP1	PHF8	Histone lysine demethylase PHF8	33.2	1	4.5	7.2	−0.27
Q13330	MTA1	Metastasis- associated protein MTA1	28.7	8	5.1	6.3	+1.55
Q59G93	BRD1	Bromodomain- containing protein 1	53.8	1	1.9	6.2	+0.30
Apoptotic signaling pathway							
Q8N163	CCAR2	Cell cycle and apoptosis regulator protein 2	102.9	8	10.2	57.1	+0.51
Q8IX12	CCAR1	Cell division cycle and apoptosis regulator protein 1	131.4	5	3.1	30.9	+1.56
Q9BZZ5	API5	Apoptosis inhibitor 5	37.5	4	10.0	27.2	+2.22

continued on next page

continued on next page

UniProtKB accession no.	Spot name	Description	Theoretical mass (kDa)	MaxQuant search results			Log fold change Cancer versus normal*
				No. of matched peptides	Sequence coverage (%)	Score	
Q9UKV3	ACIN1	Apoptotic chromatin condensation inducer in the nucleus	122.5	3	3.8	19.9	−2.24
D6RC06	HINT1	Histidine triad nucleotide- binding protein 1	7.3	1	21.5	6.7	+0.84
Transformation signaling pathway							
G3XAM7	CTNNA1	Catenin α -1	92.7	6	8.8	76.4	−1.01
B4DSW9	CTNNB1	Catenin β -1	77.5	3	3.9	24.3	+0.13
O00499	BIN1	Myc box- dependent interacting protein 1	43.2	1	3.6	6.3	−1.12

*Average log fold differences between PAX8-associated proteins in the cancer relative to normal cells (+, higher in cancer; −, higher in normal).

p66 α (GATAD2A), metastasis-associated protein 2 (MTA2), histone deacetylase 1 (HDAC1), and retinoblastoma binding protein 4 (RBBP4). These proteins are components of the nucleosome remodeling and deacetylase (NuRD) complex, which is responsible for transcriptional repression through histone deacetylation and nucleosome remodeling (28). Some of these proteins (such as HDAC1 and RBBP4) were found at highly different levels between normal and cancer cells (more than 100-fold; Fig. 1D and Table 1).

To prioritize the putative PAX8-interacting partners for further study, we ranked the peptides by confident identification score (MaxQuant score), correlation with PAX8 expression in ovarian tumor tissues, and co-dependency in ovarian carcinoma cell lines. SOX17, a member of the Sry-related HMG box transcription factor family, exhibited the strongest correlation and co-dependency with PAX8 in ovarian cancer and was identified among the top-ranked most abundant putative PAX8-interacting partners (Table 1 and fig. S1). We confirmed SOX17 as a bona fide PAX8-interacting partner by coimmunoprecipitation using agarose beads covalently bound to either a specific antibody to PAX8 or an antibody to SOX17, compared to rabbit immunoglobulin G (IgG) control beads (Fig. 1E), indicating that PAX8 and SOX17 physically interact. In addition, the level of PAX8-SOX17 complexes was markedly increased in HGSOC compared to FTSECs. Consistent with this finding, we observed coelution of PAX8 and SOX17 in the same large molecular size fractions from the Sephacryl S-300 column (Fig. 1F), indicating that they are part of the same complex. We did not observe monomeric PAX8 or SOX17 in lower-molecular weight fractions.

PAX8 physically interacts with SOX17 in HGSOC

We next characterized the location and levels of expression of PAX8 and SOX17 in five normal human fallopian tube tissues and in five different HGSOC cases by immunohistochemistry. In normal tissues, we observed the coexpression of PAX8 and SOX17 in the FTSECs (Fig. 2A). We also observed more abundant expression of both PAX8 and SOX17 in all HGSOC cases (Fig. 2A). Analysis of

public datasets in the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) portal revealed that PAX8 and SOX17 gene expression levels were significantly higher in ovarian cancers and in benign fallopian tubes than in normal ovaries (fig. S2, A and B).

Our immunohistochemical findings were supported by high-resolution immunofluorescence analyses showing the nuclear colocalization of PAX8 and SOX17 in three different immortalized fallopian tube secretory cell lines (FT194, FT246, and FT282) and three HGSOC cell lines (OVCAR4, KURAMOCHI, and OVSAHO) (Fig. 2B). To visualize the direct interaction of PAX8 and SOX17, we performed an in situ proximity ligation assay (PLA), which enables the identification of both stable and transient protein interactions. We confirmed increased interaction between PAX8 and SOX17 in all the tested HGSOC cell lines: OVCAR4, KURAMOCHI, and OVSAHO (Fig. 2C and fig. S2D). As expected for transcription factors, the observed protein-protein interactions were localized in the nuclei. Moreover, we explored the PAX8-SOX17 interaction in five different HGSOC tissue samples, and again, we observed a stronger and higher number of PLA signals in the cancer samples than in the normal fallopian tube samples (Fig. 2D), suggesting that the PAX8-SOX17 interaction may be enhanced in the process of malignant transformation. Moreover, in the normal fallopian tube cases, the PLA signals (PAX8-SOX17 interaction) were restricted to the secretory cells, reinforcing the hypothesis that these cells are the site of origin for HGSOC.

Mutual regulation of PAX8 and SOX17

To assess the transcriptional relationship between SOX17 and PAX8, we used RNA interference. Knockdown of PAX8 or SOX17 was achieved with a small interfering RNA (siRNA) pool of four individual siRNAs and confirmed by each siRNA individually. Nontargeting siRNAs served as negative controls. After PAX8 knockdown, SOX17 protein levels were greatly reduced in all tested FTSEC and HGSOC cell lines (Fig. 3, A and B, and fig. S3). Conversely, SOX17 knockdown also led to a decrease in the PAX8 protein level, but




Fig. 2. PAX8 physically interacts with SOX17 in human fallopian tube and ovarian cancer tissues. (A) Immunohistochemistry showing nuclear coexpression of PAX8 and SOX17 in FTSEC and HGSOV. Five different benign fallopian tube samples and five different ovarian cancer patient samples were analyzed, and one representative case of each is shown. Scale bar, 10 μ m. H&E, hematoxylin and eosin. (B and C) Immunofluorescence (B) and PLA (C) assessing colocalization of PAX8 and SOX17 in secretory cells (FT194, FT246, and FT282) and carcinoma cells (OVCAR4, KURAMOCHI, and OVSAHO). Scale bars, 10 μ m. The nuclei were acquired in one z plane with $\times 60$ magnification. Images are representative of duplicate experiments, 100 cells analyzed in each. (D) In situ PLA signals (dark brown puncta) in normal fallopian tube sections and HGSOV samples. Nuclei are visible as light brown in the background and were acquired in one z plane with $\times 40$ magnification. These experiments were performed on the same 10 cases from (A), and representative sections are shown. Scale bar, 100 μ m.

the effects were less pronounced. At the RNA level, PAX8 loss led to a significant decline of SOX17 expression in all cell lines studied (Fig. 3C) and SOX17 knockdown similarly led to a decrease of PAX8 expression (Fig. 3D). These data suggest that SOX17 and PAX8 can transcriptionally regulate each other's mRNA expression and that, in the absence of PAX8, SOX17 protein is rapidly depleted.

To determine whether the PAX8-SOX17 complex transcriptionally regulates the PAX8 and SOX17 promoters, we performed a luciferase reporter assay to directly test the transcriptional effect of this complex on a minimal promoter containing five copies of the PAX8-binding sites (29). Consistent with the results described above, knockdown of either PAX8 or SOX17 demonstrated a significant decline of luciferase activity mediated by PAX8-binding sites (Fig. 3, E and F).

PAX8 and SOX17 regulate a common set of genes

To determine which pathways are regulated by the PAX8-SOX17 complex, we performed RNA sequencing (RNA-seq) in OVCAR4 cells after depletion of each factor individually or after simultaneous depletion of both. Control cells received two independent nontargeting siRNA control pools. The efficiency of the knockdowns was assessed by both the number of sequenced reads and Western blot. Unsupervised analysis of the significantly altered transcripts after the loss of PAX8, SOX17, or both is shown (Fig. 4A), and the complete list of genes is included in table S1. PAX8 target genes were significantly more likely than expected by chance to also be SOX17 target genes ($P < 0.00001$, chi-square test). PAX8 and SOX17 can both negatively and positively regulate gene expression, although a majority of the significantly altered genes were down-regulated after knockdown of PAX8, SOX17, or both. Treatment with siRNAs to simultaneously deplete both factors largely phenocopied the maximal effect of either siPAX8 or siSOX17 (Fig. 4A). We focused on the 380 genes that were commonly up-regulated (Fig. 4B) under all three conditions (absolute $\log_2$ fold change ≥ 1 , adjusted $P < 0.05$). These genes were enriched in pathways associated with cell adhesion, motility, blood vessel development, and angiogenesis (Fig. 4C).

To further characterize the gene regulation coordinated by PAX8/SOX17, we





Fig. 3. PAX8 and SOX17 are mutually regulated. (A and B) Immunoblot analyses for PAX8 or SOX17 after each protein's knockdown in three different FTSECs and three different HGSOCS cells. A representative blot of three independent experiments is shown, and these results are representative of those obtained in three FTSEC (FT194, FT246, and FT282) and three HGSOCS (OVCAR4, KURAMOCHI, and OVSAHO) lines. (C and D) Real-time PCR analysis after knockdown of PAX8 or SOX17 in FTSECs (FT194, FT246, and FT282) and HGSOCS cells (OVCAR4, KURAMOCHI, and OVSAHO) depicting the transcriptional coregulation of SOX17 by PAX8. Data are means $\pm$ SD from three independent experiments in each cell line. (E and F) Luciferase reporter assay using vector containing 5× PAX8 recognition sequence in cells with or without PAX8 or SOX17 knockdown. Data are shown for OVCAR4 and FT194 and are means $\pm$ SD from three independent experiments done in triplicate. P values by unpaired *t* tests (C and D) and one-way ANOVA (E and F).

performed targeted functional proteomic profiling using reverse-phase protein array (RPPA). Knockdown of PAX8, SOX17, or both resulted in significant changes across 142 proteins ($P < 0.01$; Fig. 4D and table S2). Consistent with our observations made using RNA-seq,

ontology analysis of the identified target proteins showed that cell adhesion and angiogenesis were among the pathways most significantly altered after PAX8 and/or SOX17 loss (fig. S4A). When examining individual genes, we found that the gene encoding Serpin



family E member 1 (*SERPINE1*)—also known as plasminogen activator inhibitor 1 (*PAI1*) and implicated as an inhibitor of the tissue-type plasminogen activator and angiogenesis (30)—was the most highly increased protein after PAX8/SOX17 knockdowns (Fig. 4E and table S2). The protein data corroborated the RNA-seq analysis, which also found *SERPINE1* mRNA levels as one of the most significantly up-regulated genes after depletion of PAX8, SOX17, or both factors simultaneously by 80 to 95% (fig. S4, B and C). Using immunoblotting and quantitative polymerase chain reaction (PCR), we confirmed that PAX8 or SOX17 knockdown significantly increased the expression of *SERPINE1* at both the mRNA and protein level in all tested cell lines (Fig. 4, F and G). Moreover, *SERPINE1* presented a strong differential expression pattern between benign and malignant cells. All FTSEC lines exhibited higher levels of *SERPINE1* compared to isogenic oncogene-transformed lines or ovarian cancer cell lines (fig. S4C), and this expression was inversely correlated with the levels of PAX8 and SOX17 (fig. S4D). This suggests an important role for PAX8-SOX17-mediated *SERPINE1* suppression in malignant transformation. Consistent with these observations, we identified PAX8- and SOX17-binding sites at the *SERPINE1* locus using ChIP-seq (Fig. 4H), and using the GeneHancer database (31), we found that these sites are predicted to interact with enhancers associated with the *SERPINE1* promoter.

The angiogenesis regulator, *SERPINE1*, is regulated by PAX8-SOX17

Using an angiogenesis antibody array, we further examined the levels of 35 different secreted angiogenesis mediators in a panel of human ovarian carcinoma cells (OVCAR3, OVCAR4, KURAMOCHI, and OVTOKO) and a panel of human fallopian tube secretory cells (FT33, FT194, FT246, and FT282). The FTSEC line-conditioned media exhibited a higher concentration of the angiogenesis inhibitors, such as *SERPINE1* and *THBS1*, whereas the ovarian cancer lines secreted more angiogenesis inducers, such as vascular endothelial growth factor (VEGFA), CXCL8, and CXCL16 (Fig. 5A). We found that some angiogenic factors appeared to be regulated by PAX8 and SOX17. The secretion of VEGFA, CXCL8, and CXCL16 was decreased after PAX8 or SOX17 knockdown in the cancer lines, whereas their secretion in the normal lines was not detected (Fig. 5B). However, the most prominent effect observed in cancer cell lines was a large increase in *SERPINE1* secretion after PAX8 knockdown (Fig. 5B and fig. S5). Basal *SERPINE1* secretion was increased in FTSECs compared to ovarian cancer lines, with FTSEC-conditioned media containing *SERPINE1* with an average of 20 ng/ml compared to an average of 0.2 ng/ml for ovarian cancer cell lines (Fig. 5, C and D). Corroborating our findings, the secretion of *SERPINE1* was significantly increased in HGSOC-conditioned media after knockdown of PAX8 or SOX17 (Fig. 5, E and F). Furthermore, analysis of the ovarian cancer samples in the TCGA showed a strong negative correlation between *SOX17* and both *SERPINE1* and *THBS1* (fig. S6).

PAX8 and SOX17 influence angiogenesis through regulation of *SERPINE1*

Conditioned media from ovarian carcinoma cells induced tube formation by human umbilical vein endothelial cells (HUVECs) in culture, although not to the same extent as in response to recombinant VEGF. This effect was almost abolished in conditioned media from ovarian cancer lines depleted of PAX8 or SOX17 (Fig. 6A). However, no induction of tube formation was observed in HUVECs

cultured in conditioned media from FTSEC lines, which exhibit a higher concentration of *SERPINE1* (Fig. 6, A and B).

To determine whether the effect of PAX8 and SOX17 on tube formation is mediated by *SERPINE1*, we knocked down *SERPINE1* in FTSECs and in HGSOC lines, in combination with PAX8 or SOX17 knockdown (Fig. 6C). *SERPINE1* knockdown in FTSECs led to a marked increased ability of the conditioned media to induce tube formation, highlighting the important role of this protein in preventing angiogenesis induction by fallopian tube cells. PAX8 or SOX17 knockdown did not impair the effects of *SERPINE1* knockdown in these cells. In contrast, *SERPINE1* knockdown in HGSOC rescued the angiogenesis decrease caused by PAX8 or SOX17 knockdown, indicating that *SERPINE1* represents a critical mediator of the effects of these transcription factors on angiogenesis. To confirm these results using an orthogonal assay, we used the spheroid sprouting assay to quantify angiogenesis in a three-dimensional (3D) micro-environment (Fig. 6D). Consistent with the tube formation assay, we observed inhibition of sprouting by conditioned media from OVCAR4 upon PAX8 or SOX17 knockdown. However, this inhibition was rescued, at least partially, by the simultaneous knockdown of *SERPINE1*. Last, a chemoinvasion assay was performed on HUVEC cells to assess the effects of *SERPINE1*, PAX8, or SOX17 knockdown on the ability of cancer cells to induce invasion in vascular endothelial cells (Fig. 6E). We observed that *SERPINE1* knockdown in FTSECs could increase invasion and that this effect could not be reversed by PAX8 or SOX17 knockdown. In HGSOC cells, PAX8 or SOX17 knockdown decreased invasion of vascular endothelial cells, a phenotype partially rescued by *SERPINE1* knockdown, again demonstrating the importance of *SERPINE1* on the downstream effects of PAX8 and SOX17.

To extend these findings to an *in vivo* model, we performed the directed *in vivo* angiogenesis assay (DIVAA) (32, 33) in nude mice. DIVAA uses semiclosed small silicone cylinders (angioreactors), which can be filled with angiogenic or antiangiogenic compounds of interest. After subcutaneous implantation in nude mice (Fig. 7A), host vascular endothelial cells will migrate into the angioreactors and proliferate to form new blood vessels if the compound of interest is angiogenic. In the presence of VEGF, used as a positive control, a strong induction of angiogenesis was observed (Fig. 7, A and B). No substantial blood vessels were observed in the vehicle [phosphate-buffered saline (PBS) or fresh medium] control or with *SERPINE1*. Angioreactors containing OVCAR4-conditioned media revealed extensive angiogenesis, whereas the conditioned media from fallopian tube cells FT194 had no effect. The presence of erythrocytes inside the newly developed blood vessels in OVCAR4 angioreactors indicated that they were functional. In contrast, conditioned media from HGSOC cell lines in which PAX8 or SOX17 was knocked down showed a significant decrease in ovarian cancer-induced neovascularization. These results show that ovarian cancer cell lines have the capacity to induce angiogenesis *in vivo* and that PAX8 and SOX17 are crucial in this process (Fig. 7C).

DISCUSSION

Previous studies have shown that benign and malignant cells are distinguished by marked remodeling of the PAX8 cistrome, implying that PAX8 may acquire new targets or functions in the malignant state (25, 34). We analyzed benign and malignant cells to investigate whether the PAX8 redistribution in cancer cells was due




Fig. 5. PAX8 and SOX17 regulate the secretion of angiogenesis mediators. (A) Human angiogenesis array of conditioned media from FT194 and OVCAR4 cells after PAX8 or SOX17 knockdown. (B) Effect of PAX8 knockdown on specific analytes was produced by quantifying the array membrane spot intensity. (C and D) ELISA for quantification of secreted SERPINE1 (C) and VEGF (D) in the FT194- and OVCAR4-conditioned media. (E) ELISA showing SERPINE1 secreted by FTSEC and HGSOC. (F) ELISA experiments showing the effects of PAX8 or SOX17 knockdown on levels of SERPINE1 in HGSOC. Data in (E) and (F) are means and SD from three independent experiments done in duplicate. In (A) and (B), representative data from FT194 and OVCAR4 cells are shown, as one of three experiments in each cell line done in triplicate. In (C) and (D), representative data from FT194 and OVCAR4 are shown (done in duplicate in each cell line). In (E) and (F), representative data from cell lines are shown, from three experiments each in duplicate; *P* values by one-way ANOVA.

to changes in the PAX8 network and to further clarify its roles in ovarian cancer. Its crucial role in transcriptional regulation was highlighted by our finding that multiple chromatin remodeling proteins interact with PAX8, including several subunits of the NuRD complex CHD4, MTA2, GATAD2A, GATAD2B, HDAC1, and RBBP4. Whereas many of the interacting proteins were present in both benign and malignant PAX8 complexes, their relative abundance differed, highlighting the likely reprogramming of PAX8 previously reported (25, 34). Furthermore, frequent copy number gains at the PAX8 locus correlate with PAX8 mRNA levels, and a super-enhancer at the PAX8 locus likely helps to sustain high-level expression in tumors (35, 36). Acquired somatic mutations within the regulatory elements upstream of PAX8 and within elements bound by PAX8 likely also contribute to dysregulation of PAX8 and target genes in advanced tumors (26). NuRD complex core members, such as the helixase CHD4, were also found to be interactors and epigenetic coregulators of PAX3-FOXO1 in alveolar rhabdomyosarcoma (37). Reinforcing these findings, PAX8 levels are strongly decreased by inhibitors of HDAC1 (36).

Among the interacting partners identified, SOX17 was one of the most highly enriched in our MS data. Analysis of TCGA data indicates that SOX17 strongly correlates with PAX8 in ovarian cancer, and both genes are frequently amplified in HGSOC, often coincidentally. SOX17 is a transcription factor and member of the SOXF family, which has high mobility group (HMG), β -catenin-binding, and transactivation domains (38). Its biological function is dependent on a dimerization partner that is dynamic and specific to the cell context (39). SOX17-interacting partners can engage differentially in the genome, regulating different sets of genes (40). Therefore, we hypothesized that a PAX8-SOX17 transcriptional complex functions in both benign and malignant




Fig. 6. PAX8 and SOX17 promote ovarian cancer angiogenesis. (A) Tube formation assay in HUVECs after culture with recombinant VEGF, recombinant SERPINE1, and conditioned media from FT194 or OVCAR4 cells with and without PAX8 or SOX17 knockdown. Images are representative of experiments done in triplicate. Scale bar, 100 μ m. (B) Quantitation of the HUVEC neovessel loops from (A). Data are from three different experiments done in triplicate. (C) Endothelial cell tube formation after treatment with conditioned media from FT194 and OVCAR4 cells with the following knockdowns: PAX8, SOX17, SERPINE1, dual SERPINE1 + PAX8, or dual SERPINE1 + SOX17. Images are representative of three independent experiments. (D) 3D angiogenic sprouting 7 days after the addition of conditioned media from OVCAR4 cells in which PAX8, SOX17, SERPINE1, or a combination (PAX8, SOX17, SERPINE1) was knocked down. Images are representative of three independent experiments done in triplicate. (E) Invasion by endothelial cells in the presence of conditioned media (CM) from FT194 or OVCAR4 cells with the indicated knockdowns. Data are means and SD from three experiments done in triplicate. *P* values noted in (B) and (E) were obtained by one-way ANOVA.

secretory cells and is important in ovarian tumorigenesis. Our findings concur with the current literature showing that PAX and SOX members can engage in transcriptional regulation. PAX3

and SOX10 can physically interact and synergistically regulate MITF and c-RET enhancers (41). The PAX3-SOX10 interaction is important for melanoma cells, where these factors regulate cell motility, apoptosis,




Fig. 7. PAX8 and SOX17 promote ovarian cancer-directed angiogenesis in vivo. (A) Neovascularization is observed in angioreactors containing conditioned media from HGSOC (OVCAR4) cells, but not from FTSEC (FT194) after implantation in nude mice. (B) Quantitation of host endothelial cell invasion into angioreactors. In (A) and (B), $n = 5$ mice per group. P values are indicated by one-way ANOVA analysis. (C) Proposed model wherein suppression of SERPINE1 expression by PAX8-SOX17 in the malignant state enables unfettered angiogenesis by VEGF and other proangiogenic factors.

and proliferation (42). In addition, PAX6 and SOX2 are also interacting partners in early neural differentiation and are necessary for neural progenitor cell pluripotency (43). Furthermore, PAX6 and SOX2 act as an oncogene and can induce cancer cell stemness (44).

We found that PAX8 and SOX17 can mutually regulate each other at the transcriptional level. At the protein level, PAX8 knockdown led to an almost complete disappearance of SOX17, and SOX17 knockdown led to a substantial decrease in PAX8 levels. These results are consistent with our previously reported findings that PAX8 and SOX17 are master transcription factors that occupy regulatory elements related to their own encoding genes in ovarian cancer

(45). Globally, PAX8 and SOX17 genomic binding sites colocalize within candidate active enhancers in HGSOC cell lines. In addition, PAX8 binds near the SOX17 gene locus, which confirms the coregulation observed in SOX17 transcript and protein levels (45). Our transcriptomic and proteomic analyses revealed that PAX8 and SOX17 commonly regulate a family of genes associated with blood vessel formation, suggesting a cooperative role in orchestrating an important proangiogenic transcriptional program in ovarian cancer. In this setting, it may be interesting to note that SOX17 was found overexpressed in highly vascularized human glioblastoma and that murine Sox17 can promote tumor angiogenesis (46).

Our analysis of PAX8/SOX17 target genes revealed SERPINE1 to be the most highly and commonly up-regulated at both the transcript and protein levels. SERPINE1 is a serine proteinase inhibitor, belonging to the Serpin family, which is an important endothelial plasminogen activator inhibitor and urokinase inhibitor (47). Important roles in coagulation, extracellular matrix remodeling, and angiogenesis have been reported for SERPINE1. The antiangiogenic effects of SERPINE1 seem to be mediated by binding to vitronectin and blocking integrin $\alpha v\beta 3$ - and urokinase plasminogen activator surface receptor (uPAR)-binding sites (48). Therefore, binding of secreted SERPINE1 to vitronectin blocks cell adhesion and migration and inhibits angiogenesis (49). Moreover, SERPINE1 can inhibit VEGF receptor 2 (VEGFR-2) activation by blocking the proangiogenic binding interaction between VEGFR-2 and integrin $\alpha v\beta 3$ (50). Therefore, this regulation of the VEGF pathway by SERPINE1 is notable, as VEGF is a potent mediator of tumor angiogenesis in various tumors, and ovarian cancer patients with high levels of VEGF have been reported to have worse prognoses and lower survival rates. Note that SERPINE1 has been reported to have both pro- and antiangiogenic function, with the amounts of SERPINE1 being a major determinant in these effects (47). Our results show that in ovarian cells, SERPINE1 is an essential inhibitor of tumor angiogenesis, which is down-regulated upon activation of PAX8-SOX17 signaling. On the basis of these experiments, we hypothesize that suppressing SERPINE1 through malignant transformation triggers VEGF pathway activation in vivo and contributes to tumor angiogenesis (Fig. 7C).

Our results may also help explain some of the developmental defects described in the *Pax8* knockout mouse (16). *Pax8*^{-/-} mice are infertile because they lack a functional uterus, revealing only remnants of myometrial tissue. In addition, the vaginal opening is absent. Folliculogenesis, ovarian hormone production, and transcription of pituitary hormones are in a normal range. Thus, infertility in *Pax8*^{-/-} mice seems to be due to a defect in development of the reproductive tract rather than to hormonal imbalance, pointing to a direct morphogenic role for PAX8 in uterine development. Our observation that PAX8 and SOX17 orchestrate an angiogenic program may help explain the atresia of the reproductive tract seen in the *Pax8*^{-/-} mice. The absence of Pax8 in the developing reproductive tract is likely accompanied by low SOX17 and high SERPINE1. These conditions would effectively shut down blood vessel development and prevent the development of the organ. This is reminiscent of the severe embryopathy seen with thalidomide in the early 1960s (51). Thalidomide was marketed as an antiemetic, which was later shown to have antiangiogenic properties that cause severe birth defects, including phocomelia (limb defects) and genital and internal organ absence or malformation.

Current evidence supports a model by which various PAX8 interactions will control different cellular functions (18). For example, the interaction between PAX8 and MECOM is crucial in cell adhesion and cellular matrix regulation in ovarian cancer (52). Here, we have shown that PAX8 physically interacts with SOX17 in FTSEC and HGSOc, leading to changes in multiple transcriptional programs, including modulation of genes mediating tumor angiogenesis. Using in vitro and in vivo angiogenesis assays, we demonstrated that PAX8/SOX17 can regulate angiogenesis during tumor development and that SERPINE1 is a crucial mediator of this effect. Overall, our work suggests that inhibition of the PAX8/SOX17 pathway may be of potential value as part of an antiangiogenic approach to the treatment of ovarian cancer.

MATERIALS AND METHODS

Cells and tissues

Human immortalized fallopian tube secretory cells (FT33, FT194, FT246, FT282, and FT282-E) were maintained in standard conditions as previously described (53) and grown in Dulbecco's modified Eagle's medium (DMEM)/F-12 containing 2% Ultrosor G serum substitute. OVCAR3 was obtained from the American Type Culture Collection (ATCC); OVCAR4 was acquired from W. C. Hahn's laboratory—Cancer Cell Line Encyclopedia (Dana-Farber Cancer Institute); JHOS2 was from G. Konecny (University of California, Los Angeles); and KURAMOCHI, OVSAHO, and OVTOKO were obtained from Japanese Collection of Research Bioresources Cell Bank (Japan). All lines were maintained as recommended by the supplier. HUVECs were acquired from Sigma-Aldrich and maintained according to the manufacturer's instructions. All cell lines were sent to the Wistar Institute Genomic Core Facility for authentication using short tandem repeat profiling and for detection of *Corynebacterium bovis* infection. In addition, all cell lines were also tested for *Mycoplasma* sp. at the University of Pennsylvania Cell Center.

After approval by the Hospital of Pennsylvania Institutional Review Board, we obtained human fallopian tube and human HGSOc formalin-fixed and paraffin-embedded sections from the Department of Pathology at Hospital of the University of Pennsylvania to evaluate the expression of PAX8 and SOX17.

Purification of endogenous PAX8

Benign and malignant cells were grown in 15-cm plates until 90% confluence, washed twice with PBS, trypsinized, neutralized, and collected. Nuclear fractionation was prepared as previously published (27). Harvested cells were resuspended in hypotonic buffer [20 mM Hepes (pH 7.5), 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1.5 mM MgCl₂, 2 mM dithiothreitol, protease inhibitors (Sigma-Aldrich, P8340), and phosphatase inhibitors (Sigma-Aldrich, P5726)] and incubated for 30 min. Samples were then disrupted through a 22-gauge needle and centrifuged at 10,000g for 10 min at 4°C. Nuclei-enriched fraction was sonicated with complete radioimmunoprecipitation assay (RIPA) buffer (Cell Signaling Technology, 9806S) containing protease inhibitors (Sigma-Aldrich, P8340) and phosphatase inhibitors (Sigma-Aldrich, P5726) and spun down for 10 min at 10,000g at 4°C. The supernatant (500 μ g of nuclear extract) was incubated for 16 hours at 4°C with 105 μ g of PAX8-specific antibody (Proteintech, 10336-1-AP) coupled to 1 ml of protein A agarose resin (Thermo Fisher Scientific, 44893) or with 105 μ g of normal rabbit IgG (Proteintech, 30000-0-A) coupled to 1 ml of protein A agarose resin as a negative control. The columns were washed three times with 10 ml of 0.1 M phosphate and 0.15 M NaCl (pH 7.2) and eluted with 0.5 M NaCl and 0.1 M glycine (pH 2.8). Fractions had their pH equilibrated with 1 M tris (pH 9.5), separated by gel electrophoresis, and Coomassie blue-stained, and lanes were sent for MS analysis.

The affinity column eluates containing PAX8 were also loaded onto a 100-ml Sephacryl S-300 column (Sigma-Aldrich, S300HR-100ML) equilibrated with 50 mM tris (pH 7.5), 100 mM KCl, 0.5 M NaCl, 1% NP-40, and 1% glycerol. We collected one hundred fifty 500- μ l fractions; protein peaks were separated by gel electrophoresis, silver-stained (Thermo Fisher Scientific, 24600), and checked by Western blots for the presence of PAX8; and PAX8-positive fractions were also submitted for MS analysis.

Identification of PAX8-interacting partners

Coomassie blue-stained lanes containing PAX8 were analyzed by nanoLC-MS/MS setup as previously described (54). In summary,

high-performance liquid chromatography gradient was set between 0 and 30% of solvent A (0.1% formic acid) and solvent B (95% acetonitrile, 0.1% formic acid) for 1 hour followed by 5 min of 30 to 85% of solvent B and 10 min of isocratic 85% solvent B. Flow rate of nano-scale liquid chromatographic tandem mass spectrometry (nLC-MS/MS) was set to 300 nL/min and coupled to an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific, USA) with 2.5-kV spray voltage and 275°C of capillary temperature. Full MS was performed using a resolution of 120,000 and 27 of higher-energy C-trap dissociation (HCD). Digital differential analyzer (DDA) files were analyzed with MaxQuant (55) using a SwissProt human database. Intensity based absolute quantification (iBAQ) was used for enrichment analysis, and data were log₂-transformed and normalized by subtracting the average of all valid values for each sample. Statistical analysis was obtained by applying a two-tailed heteroscedastic *t* test.

TCGA and GTEx expression analysis

RNA-seq data from TCGA and GTEx were retrieved using databank links (<https://xenabrowser.net/> and <https://gtexportal.org/home/>). From the available data types, gene expression was selected for Fallopian tube (FT), Ovary (OV), Serous Ovarian Carcinoma (SOC), and TCGA Ovarian Cancer (TCGA-OV). Using GraphPad Prism unpaired *t* test, PAX8 and SOX17 expression was analyzed and adjusted *P* < 0.001 was reported as statistically significant.

Protein-protein interaction analysis in situ

Before the protein-protein interaction staining by in situ PLA, tissue sections and cell lines were processed as described in the “Immunohistochemistry” and “Immunofluorescence” sections. PLA signals were determined using Duolink Probes Anti-Mouse MINUS (Sigma-Aldrich, DUO92004) and Anti-Rabbit PLUS (Sigma-Aldrich, DUO92002) according to the manufacturer’s recommended protocol after overnight incubation with antibody to mouse PAX8 at 1:250 (Novus, NBP2-29903) and to rabbit SOX17 at 1:250 (Cell Signaling Technology, 81778S) at 4°C. Red fluorescent signals were obtained using detection reagent red (Sigma-Aldrich, DUO92008), and chromogen signals were acquired using detection reagent brightfield (Sigma-Aldrich, DUO92012).

siRNA knockdown

All knockdowns were performed by reverse transfection using a pool of four siRNAs that were individually deconvoluted and validated. Fallopian tube secretory cells (300,000) or ovarian carcinoma cells (300,000) were incubated with 10 µL of Lipofectamine RNAi-Max (Thermo Fisher Scientific, 13778075) and 30 nM of the respective siRNA [ON-TARGETplus Human PAX8 siRNA (Dharmacon, L-003778-00-0005), ON-TARGETplus Human SOX17 siRNA (Dharmacon, L-013028-01-0005), or nontargeting siRNA as negative control (Dharmacon, D-001810-10-05)] in Opti-MEM reduced serum medium (Gibco, 31985088) as recommended by the manufacturer’s protocol.

Immunohistochemistry

Fallopian tube and high-grade ovarian carcinoma sections were processed as previously reported (55). The immunohistochemical staining was performed using a dilution of 1:500 of antibodies to PAX8 (Novus, NBP1-32440) or SOX17 (Novus, NBP1-47996). Slides were scanned with Aperio CS2.

Immunofluorescence

A total of 10⁴ cells from each FTSEC and HGSOc line were seeded onto imaging plates (Eppendorf, 0030741030) and allowed to grow for 24 hours. Cells were washed twice in PBS, and fixation was performed for 15 min with 4% paraformaldehyde (Thermo Fisher Scientific, AAJ19943K2) at room temperature. Cells were then washed twice in PBS and permeabilized with 0.25% Triton X-100 (Boston BioProducts, P-924) for 15 min. Aldehyde residues were quenched with 100 mM glycine (Sigma-Aldrich, 50046-50G) for 15 min. The unspecific sites were blocked with a solution of 1% bovine serum albumin and 0.1% Tween 20 in PBS for 30 min. Samples were incubated for 16 hours at 4°C with a dilution of 1:500 of antibody to PAX8 (Novus, NBP1-32440) or SOX17 (Novus, NBP1-47996). Cells were then washed three times for 5 min each in a solution of 1% bovine serum albumin and 0.1% Tween 20 in PBS followed by incubation for 1 hour with Alexa Fluor 488–conjugated anti-mouse IgG antibody or Alexa Fluor 594–conjugated anti-rabbit IgG antibody. Cells were washed three times in PBS and mounted in Fluoromount-G with 4',6-diamidino-2-phenylindole (DAPI), and images were acquired at ×60 magnification with a Nikon Eclipse Ti inverted microscope.

Western blot analysis

Samples were incubated with RIPA buffer (Cell Signaling Technology, 9806S) for 30 min at 4°C followed by centrifugation at 10,000g for 5 min. Supernatants’ protein concentration was estimated by bicinchoninic acid method (Thermo Fisher Scientific, 23227). Thirty micrograms of each sample was mixed with sample buffer loaded and separated using Mini-PROTEAN TGX 4 to 15% polyacrylamide gels (Bio-Rad, 4561083) and tris/glycine/SDS buffer (Bio-Rad, 1610732). Turbo transfer system (Bio-Rad, 1704156) was used to move separated samples from gels to polyvinylidene difluoride (PVDF) membranes. Primary antibodies to PAX8 (Novus, NBP1-32440), SOX17 (Abcam, ab224637), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cell Signaling Technology, 5174) were diluted 1:1000 in 5% nonfat milk in tris-buffered saline (TBS) containing 0.1% Tween 20 and incubated with the membranes overnight at 4°C. Membranes were then washed three times in TBS containing 0.1% Tween 20 and then incubated with horseradish peroxidase (HRP)–conjugated anti-rabbit IgG antibody (Cell Signaling Technology, 7074). Images were acquired by chemiluminescence using Clarity ECL (Bio-Rad, 1705062).

Coimmunoprecipitation

Nuclear lysates (500 µg) were incubated with 25 µg of a specific PAX8 antibody (Novus, NBP1-32440), 25 µg of a specific SOX17 antibody (Abcam, ab224637), or 25 µg of a normal rabbit IgG (Cell Signaling Technology, 2729S) covalently coupled to activated agarose beads (Thermo Fisher Scientific, 26148) as per the manufacturer’s recommended protocol.

RNA sequencing

Transcriptome analysis of OVCAR4 cells after PAX8, SOX17, or simultaneous knockdown has been described previously (45). Briefly, ovarian carcinoma cells had their RNA chemically purified using the Nucleospin RNA Plus Kit (Macherey-Nagel, 740984.50) as recommended by the manufacturer’s protocol. A polyadenylated nonstranded library was prepared using the newly extracted RNA, and 40 million reads were sequenced by BGI platform. Bioinformatic analyses were executed using the R package DESeq2 (version 1.24.0). Significant

changes were designated as log₂ fold change ≥ 1 and adjusted $P \leq 0.01$. Metascape tool was used to identify the differentially enriched pathways.

Conditioned medium

Secretory cells and carcinoma cells were grown in 60-mm dish at 37°C and 5% CO₂. Conditioned media were retrieved by spinning down at 2000g for 5 min at 4°C, and then supernatants were passed through a 0.22- μ m filter (Millipore, SLGP033RS).

Angiogenesis array and ELISA

Secreted angiogenesis mediators were identified in fallopian tube secretory cell- and ovarian carcinoma cell-conditioned media using the Human Angiogenesis Antibody Array (R&D Systems, ARY007). Enzyme-linked immunosorbent assays (ELISAs) were used for the precise quantification of VEGF (R&D Systems, DVE00) and SERPINE1 (R&D Systems, DSE100) from conditioned media as recommended by the manufacturer's protocol. Fresh DMEM/F-12 or RPMI media were tested and used as a negative control.

Gene-specific occupancy by PAX8 and SOX17 using ChIP-seq analysis

We analyzed our previously reported ChIP-seq data for SOX17 and PAX8 (45) for binding of these transcription factors in the proximity of SERPINE1, and enhancer interactions were predicted using the GeneHancer database (31).

Tube formation assay

A total of 20,000 HUVECs were seeded in reduced growth factor basement membrane extract (BME)-coated 96-well plates (R&D Systems, 3470-096-K). Endothelial cells were exposed to 100 μ l of the different benign cell- or malignant cell-conditioned media, VEGF (10 ng/ml; R&D Systems, 293-VE-010), or SERPINE1 (10 μ g/ml; R&D Systems, 1786-PI-010) for 6 hours at 37°C. HUVECs were labeled with 2 μ M calcein AM as recommended by the manufacturer's protocol to facilitate the image acquisition using a Nikon Eclipse Ti inverted microscope. The number of complete endothelial loops per field was counted and compared.

Sprouting assay

Microfluidic plates (MIMETAS, 4003-400B) were used for the 3D endothelial sprouting assay as previously described (56). Briefly, collagen type I (R&D Systems, 3447-020-01) was used as the 3D scaffold. After incubation for solidification, the plate was removed from the incubator and kept sterile at room temperature before cell loading. Endothelial cells were dissociated, pelleted, and suspended in basal medium at a concentration of 2×10^7 cells/ml. Two microliters of the cell suspension was dispensed into the perfusion inlet and incubated for 45 min at 37°C and 5% CO₂. After the cells attached to the bottom of the perfusion channel, 50 μ l of the medium was added in the perfusion inlet and outlet wells and the plates were placed on a rocker platform for continuous perfusion (Perfusion Rocker, MIMETAS). Medium was refreshed three times a week. Angiogenic sprouting was stimulated with a combination of VEGF, fibroblast growth factor (FGF), phorbol 12-myristate 13-acetate (PMA), and S1P (positive control), basal medium (negative control), or OVCAR4-conditioned media after each specific knockdown for 7 days.

Invasion assay

The endothelial cell invasion was performed according to the manufacturer's recommendation (Trevigen, 3471-096-K). Using 96-well

invasion chambers, 50 μ l of cell suspension (20,000 cells) was added per well to the top chamber upon 0.1 $\times$ BME Coating Solution. Angiogenic mediators (VEGF or SERPINE1), basal media, or conditioned media after knockdowns were added to the bottom chamber and incubated for 24 hours. The detection of cell invasion was quantified using the calcein AM internalized by the endothelial cells.

In vivo angiogenesis assay

After Institutional Animal Care and Use Committee review and approval (protocol #806687), DIVAAs (R&D Systems, 3450-048-K) were performed as recommended by the manufacturer's protocol. Briefly, 6-week-old female nude mice (the Jackson Laboratory, 002019) were kept in aseptic conditions under the Stem Cell and Xenograft Core barrier at the University of Pennsylvania. Mouse cohorts were anesthetized with 2% isoflurane before the subcutaneous implantation of angioreactors, meaning a 1-cm flexible silicone cylinder. Dorsal-lateral incisions were made on each nude mouse, wherein angioreactors filled with FTSEC- or HGSOc-conditioned media, VEGF (10 ng/ml; R&D Systems, 293-VE-010), or SERPINE1 (10 μ g/ml; R&D Systems, 1786-PI-010) were subcutaneously inserted under the skin and then sutured to cover the incisions. Angioreactors were retrieved after 14 days of incubation for careful collection of the mouse endothelial cells that were attracted and invaded the cylinders. Neovascularization was quantified by staining the endothelial cells with fluorescein isothiocyanate (FITC)-lectin and measuring the intensity of fluorescence within a Thermo Fisher Scientific Fluoroskan Ascent FL fluorimeter at 485 nm. The animals' care and experimentation were performed under approved protocols and were in accordance with institutional guidelines.

Real-time PCR

Total RNA sample was purified using the RNeasy Plus Mini Kit (Qiagen, 74134), quantified, and used as a template for the synthesis of single-stranded complementary DNA (cDNA) using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, 4374966). To access the gene expression changes, we used the TaqMan Assay (Thermo Fisher Scientific, 4331182) using 100 ng of cDNA per 20 μ l of final reaction with TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific, 4444557) as recommended by the manufacturer's protocol.

Reverse-phase protein array

Arrays were performed at the Department of Bioinformatics and Computational Biology at MD Anderson Cancer Center as previously described (57, 58). The platform contains more than 300 antibodies exclusively validated with a Pearson coefficient > 0.7 of correlation between RPPA and Western blot were used in the proteomic analysis (59). Spot intensities were generated by colorimetric reaction using the Dako Cytomation-Catalyzed System.

Luciferase reporter assay

Briefly, half million cells were cotransfected with 1 μ g of PAX8 (Firefly) Luciferase reporter vector (28), 0.5 μ g of CMV-(*Renilla*) Luciferase control vector (Promega, E2261), and 30 nM PAX8, SOX17, or nontargeting siRNA using Lipofectamine 2000 (Thermo Fisher Scientific, 11668027) as recommended by the manufacturer's protocol. Plates containing the different transfected cells were incubated for 24 hours at 37°C before the luciferase activity was measured using the Dual-Glo Luciferase Detection Kit (Promega, E2920).

Statistical analysis

Representative graphics are displayed as mean and SD of experimental replicates. Significant changes $P < 0.05$ between controls and knockdowns were acquired by applying analysis of variance (ANOVA) and Student's t tests (GraphPad Prism 8).

SUPPLEMENTARY MATERIALS

www.science.org/doi/10.1126/scisignal.abm2496

Figs. S1 to S6

Tables S1 and S2

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

- R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, Cancer statistics, 2022. *CA Cancer J. Clin.* **72**, 7–33 (2022).
- J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D. M. Parkin, M. Pineros, A. Znaor, F. Bray, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int. J. Cancer* **144**, 1941–1953 (2019).
- L. Zheng, C. Cui, O. Shi, X. Li, W. Wang, Y. Li, Q. Wang, Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017. *Gynecol. Oncol.* **159**, 239–247 (2020).
- B. M. Reid, J. B. Permuth, T. A. Sellers, Epidemiology of ovarian cancer: A review. *Cancer Biol. Med.* **14**, 9–32 (2017).
- L. A. Torre, B. Trabert, C. E. DeSantis, K. D. Miller, G. Samimi, C. D. Runowicz, M. M. Gaudet, A. Jemal, R. L. Siegel, Ovarian cancer statistics, 2018. *CA Cancer J. Clin.* **68**, 284–296 (2018).
- R. Perets, R. Drapkin, It's totally tubular....riding the new wave of ovarian cancer research. *Cancer Res.* **76**, 10–17 (2016).
- J. Ducie, F. Dao, M. Considine, N. Olvera, P. A. Shaw, R. J. Kurman, I. M. Shih, R. A. Soslow, L. Cope, D. A. Levine, Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. *Nat. Commun.* **8**, 990 (2017).
- S. I. Labidi-Galy, E. Papp, D. Hallberg, N. Niknafs, V. Adleff, M. Noe, R. Bhattacharya, M. Novak, S. Jones, J. Phallen, C. A. Hruban, M. S. Hirsch, D. I. Lin, L. Schwartz, C. L. Maire, J. C. Tille, M. Bowden, A. Ayhan, L. D. Wood, R. B. Scharpf, R. Kurman, T. L. Wang, I. M. Shih, R. Karchin, R. Drapkin, V. E. Velculescu, High grade serous ovarian carcinomas originate in the fallopian tube. *Nat. Commun.* **8**, 1093 (2017).
- K. C. Wu, P. Wang, S. F. Lin, M. Zhang, Q. Song, T. Chu, B. G. Wang, R. J. Kurman, R. Vang, K. Kinzler, C. Tomasetti, Y. Jiao, I. M. Shih, T. L. Wang, Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. *J. Pathol.* **248**, 41–50 (2019).
- M. A. Eckert, S. Pan, K. M. Hernandez, R. M. Loth, J. Andrade, S. L. Volchenboum, P. Faber, A. Montag, R. Lastra, M. E. Peter, S. D. Yamada, E. Lengyel, Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube. *Cancer Discov.* **6**, 1342–1351 (2016).
- C. A. Sherman-Baust, E. Kuhn, B. L. Valle, M. Shih, R. J. Kurman, T. L. Wang, T. Amano, M. S. Ko, I. Miyoshi, Y. Araki, E. Lehmann, Y. Zhang, K. G. Becker, P. J. Morin, A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. *J. Pathol.* **233**, 228–237 (2014).
- K. W. McCool, Z. T. Freeman, Y. Zhai, R. Wu, K. Hu, C. J. Liu, S. A. Tomlins, E. R. Fearon, B. Magnuson, R. Kuick, K. R. Cho, Murine oviductal high-grade serous carcinomas mirror the genomic alterations, gene expression profiles, and immune microenvironment of their human counterparts. *Cancer Res.* **80**, 877–889 (2020).
- J. Kim, D. M. Coffey, C. J. Creighton, Z. Yu, S. M. Hawkins, M. M. Matzuk, High-grade serous ovarian cancer arises from fallopian tube in a mouse model. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 3921–3926 (2012).
- S. Stuckelberger, R. Drapkin, Precious GEMMs: Emergence of faithful models for ovarian cancer research. *J. Pathol.* **245**, 129–131 (2018).
- H. Q. Dinh, X. Lin, F. Abbasi, R. Nameki, M. Haro, C. E. Olingy, H. Chang, L. Hernandez, S. A. Gayther, K. N. Wright, P. J. Aspuria, B. Y. Karlan, R. I. Corona, A. Li, B. J. Rimel, M. T. Siedhoff, F. Medeiros, K. Lawrenson, Single-cell transcriptomics identifies gene expression networks driving differentiation and tumorigenesis in the human fallopian tube. *Cell Rep.* **35**, 108978 (2021).
- J. Mittag, E. Winterhager, K. Bauer, R. Grummer, Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. *Endocrinology* **148**, 719–725 (2007).
- A. Mayran, A. Pelletier, J. Drouin, Pax factors in transcription and epigenetic remodelling. *Semin. Cell Dev. Biol.* **44**, 135–144 (2015).
- D. Chaves-Moreira, P. J. Morin, R. Drapkin, Unraveling the mysteries of PAX8 in reproductive tract cancers. *Cancer Res.* **81**, 806–810 (2021).
- A. R. Laury, R. Perets, H. Piao, J. F. Krane, J. A. Barletta, C. French, L. R. Chirieac, R. Lis, M. Loda, J. L. Hornick, R. Drapkin, M. S. Hirsch, A comprehensive analysis of PAX8 expression in human epithelial tumors. *Am. J. Surg. Pathol.* **35**, 816–826 (2011).
- R. Perets, G. A. Wyant, K. W. Muto, J. G. Bijron, B. B. Poole, K. T. Chin, J. Y. Chen, A. W. Ohman, C. D. Stepule, S. Kwak, A. M. Karst, M. S. Hirsch, S. R. Setlur, C. P. Crum, D. M. Dinulescu, R. Drapkin, Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. *Cancer Cell* **24**, 751–765 (2013).
- E. Maniati, C. Berlato, G. Gopinathan, O. Heath, P. Kotantaki, A. Lakhani, J. McDermott, C. Pegrum, R. M. Delaine-Smith, O. M. T. Pearce, P. Hirani, J. D. Joy, L. Szabova, R. Perets, O. J. Sansom, R. Drapkin, P. Bailey, F. R. Balkwill, Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment. *Cell Rep.* **30**, 525–540.e7 (2020).
- T. Di Palma, M. G. Filippone, G. M. Pierantoni, A. Fusco, S. Soddu, M. Zannini, Pax8 has a critical role in epithelial cell survival and proliferation. *Cell Death Dis.* **4**, e729 (2013).
- D. Ghannam-Shahbari, E. Jacob, R. R. Kakun, T. Wasserman, L. Korsensky, O. Sternfeld, J. Kagan, D. R. Bublik, S. Aviel-Ronen, K. Levanon, E. Sabo, S. Larisch, M. Oren, D. Hershkovitz, R. Perets, PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma. *Oncogene* **37**, 2213–2224 (2018).
- L. H. Rodgers, E. Ö. hAinmhire, A. N. Young, J. E. Burdette, Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium. *Oncotarget* **7**, 32785–32795 (2016).
- K. M. Elias, M. M. Emori, T. Westerling, H. Long, A. Budina-Kolomets, F. Li, E. MacDuffie, M. R. Davis, A. Holman, B. Lawney, M. L. Freedman, J. Quackenbush, M. Brown, R. Drapkin, Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. *JCI Insight* **1**, e87988 (2016).
- R. I. Corona, J. H. Seo, X. Lin, D. J. Hazelett, J. Reddy, M. A. S. Fonseca, F. Abbasi, Y. G. Lin, P. Y. Mhawech-Fauceglia, S. P. Shah, D. G. Huntsman, A. Gusev, B. Y. Karlan, B. P. Berman, M. L. Freedman, S. A. Gayther, K. Lawrenson, Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer. *Nat. Commun.* **11**, 2020 (2020).
- J. M. Garcia-Heredia, E. M. Verdugo Sivanies, A. Lucena-Cacace, S. Molina-Pinelo, A. Carnero, Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy. *Oncotarget* **7**, 63611–63628 (2016).
- H. F. Allen, P. A. Wade, T. G. Kutateladze, The NuRD architecture. *Cell. Mol. Life Sci.* **70**, 3513–3524 (2013).
- E. Grimley, C. Liao, E. J. Ranghini, Z. Nikolovska-Coleska, G. R. Dressler, Inhibition of Pax2 transcription activation with a small molecule that targets the DNA binding domain. *ACS Chem. Biol.* **12**, 724–734 (2017).
- M. De Palma, D. Biziato, T. V. Petrova, Microenvironmental regulation of tumour angiogenesis. *Nat. Rev. Cancer* **17**, 457–474 (2017).
- S. Fishilevich, R. Nudel, N. Rappaport, R. Hadar, I. Plashkes, T. Iny Stein, N. Rosen, A. Kohn, M. Twik, M. Safran, D. Lancet, D. Cohen, GeneHancer: Genome-wide integration of enhancers and target genes in GeneCards. *Database* **2017**, bax028 (2017).
- H. Zhou, Y. H. Yang, J. R. Basile, Characterization of the effects of semaphorin 4D signaling on angiogenesis. *Methods Mol. Biol.* **1493**, 429–441 (2017).
- H. Zhou, Y. H. Yang, N. O. Binmadi, P. Proia, J. R. Basile, The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. *Exp. Cell Res.* **318**, 1685–1698 (2012).
- E. K. Adler, R. I. Corona, J. M. Lee, N. Rodriguez-Malave, P. Mhawech-Fauceglia, H. Sowter, D. J. Hazelett, K. Lawrenson, S. A. Gayther, The PAX8 cistrome in epithelial ovarian cancer. *Oncotarget* **8**, 108316–108332 (2017).
- K. Lawrenson, M. A. S. Fonseca, A. Y. Liu, F. Segato Dezem, J. M. Lee, X. Lin, R. I. Corona, F. Abbasi, K. C. Vavra, H. Q. Dinh, N. K. Gill, J. H. Seo, S. Coetzee, Y. G. Lin, T. Pejovic, P. Mhawech-Fauceglia, A. C. Rowat, R. Drapkin, B. Y. Karlan, D. J. Hazelett, M. L. Freedman, S. A. Gayther, H. Noushmehr, A study of high-grade serous ovarian cancer origins implicates the SOX18 transcription factor in tumor development. *Cell Rep.* **29**, 3726–3735.e4 (2019).
- K. Shi, X. Yin, M. C. Cai, Y. Yan, C. Jia, P. Ma, S. Zhang, Z. Zhang, Z. Gu, M. Zhang, W. Di, G. Zhuang, PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors. *eLife* **8**, e4306 (2019).
- M. Bohm, M. Wachtel, J. G. Marques, N. Streiff, D. Laubscher, P. Nanni, K. Mamchaoui, R. Santoro, B. W. Schafer, Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. *J. Clin. Invest.* **126**, 4237–4249 (2016).
- D. Grimm, J. Bauer, P. Wise, M. Kruger, U. Simonsen, M. Wehland, M. Infanger, T. J. Corydon, The role of SOX family members in solid tumours and metastasis. *Semin. Cancer Biol.* **67**, 122–153 (2020).

39. L. Hou, Y. Srivastava, R. Jauch, Molecular basis for the genome engagement by Sox proteins. *Semin. Cell Dev. Biol.* **63**, 2–12 (2017).
40. M. Wilson, P. Koopman, Matching SOX: Partner proteins and co-factors of the SOX family of transcriptional regulators. *Curr. Opin. Genet. Dev.* **12**, 441–446 (2002).
41. D. Lang, J. A. Epstein, Sox10 and Pax3 physically interact to mediate activation of a conserved c-RET enhancer. *Hum. Mol. Genet.* **12**, 937–945 (2003).
42. J. B. Mascarenhas, E. L. Littlejohn, R. J. Wolsky, K. P. Young, M. Nelson, R. Salgia, D. Lang, PAX3 and SOX10 activate MET receptor expression in melanoma. *Pigment Cell Melanoma Res.* **23**, 225–237 (2010).
43. S. Zhang, E. Bell, H. Zhi, S. A. M. Imran, V. Azuara, W. Cui, OCT4 and PAX6 determine the dual function of SOX2 in human ESCs as a key pluripotent or neural factor. *Stem Cell Res. Ther.* **10**, 122 (2019).
44. A. Ooki, W. Dinalankara, L. Marchionni, J. J. Tsay, C. Goparaju, Z. Maleki, W. N. Rom, H. I. Pass, M. O. Hoque, Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma. *Oncogene* **37**, 5967–5981 (2018).
45. J. Reddy, M. A. S. Fonseca, R. I. Corona, R. Nameki, F. S. Dezem, I. A. Klein, H. Chang, D. Chaves-Moreira, L. Afeyan, T. M. Malta, X. Lin, F. Abbasi, A. Font-Tello, T. Sabedot, P. Cajas, N. Rodriguez-Malavé, D.-C. L. J.-H. Seo, U. Matulonis, B. Y. Karlan, S. A. Gayther, A. Gusev, H. Noushmehr, H. Long, M. L. Freedman, R. Drapkin, B. J. Abraham, R. A. Young, K. Lawrenson, Predicting master transcription factors from pan-cancer expression data. *Sci. Adv.* **7**, eabf6123 (2021).
46. H. Yang, S. Lee, S. Lee, K. Kim, Y. Yang, J. H. Kim, R. H. Adams, J. M. Wells, S. J. Morrison, G. Y. Koh, I. Kim, Sox17 promotes tumor angiogenesis and destabilizes tumor vessels in mice. *J. Clin. Invest.* **123**, 418–431 (2013).
47. L. Devy, S. Blacher, C. Grignet-Debrus, K. Bajou, V. Masson, R. D. Gerard, A. Gils, G. Carmeliet, P. Carmeliet, P. J. Declercq, A. Noel, J. M. Foidart, The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. *FASEB J.* **16**, 147–154 (2002).
48. S. Stefansson, E. Petitclerc, M. K. Wong, G. A. McMahon, P. C. Brooks, D. A. Lawrence, Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. *J. Biol. Chem.* **276**, 8135–8141 (2001).
49. S. Stefansson, D. A. Lawrence, The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. *Nature* **383**, 441–443 (1996).
50. J. Wu, T. L. Strawn, M. Luo, L. Wang, R. Li, M. Ren, J. Xia, Z. Zhang, W. Ma, T. Luo, D. A. Lawrence, W. P. Fay, Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2- α V β 3 integrin cross talk. *Arterioscler. Thromb. Vasc. Biol.* **35**, 111–120 (2015).
51. N. Vargesson, Thalidomide-induced teratogenesis: History and mechanisms. *Birth Defects Res. C Embryo Today* **105**, 140–156 (2015).
52. M. Bleu, F. Mermet-Meillon, V. Apfel, L. Barys, L. Holzer, M. B. Salvy, R. Lopes, I. A. M. Barbosa, C. Delmas, A. Hinniger, S. Chau, M. Kaufmann, S. Haenni, K. Berneiser, M. Wahle, I. Moravec, A. Vissieres, T. Poetsch, E. Ahne, N. Carte, J. Voshol, E. Bechter, J. Hamon, M. Meyerhofer, D. Erdmann, M. Fischer, T. Stachyra, F. Freuler, S. Gutmann, C. Fernandez, T. Schmelzle, U. Naumann, G. Roma, K. Lawrenson, C. Nieto-Oberhuber, A. Cobos-Correa, S. Ferretti, D. Schubeler, G. G. Galli, PAX8 and MECOM are interaction partners driving ovarian cancer. *Nat. Commun.* **12**, 2442 (2021).
53. A. M. Karst, R. Drapkin, Primary culture and immortalization of human fallopian tube secretory epithelial cells. *Nat. Protoc.* **7**, 1755–1764 (2012).
54. P. Sen, Y. Lan, C. Y. Li, S. Sidoli, G. Donahue, Z. Dou, B. Frederick, Q. Chen, L. J. Luense, B. A. Garcia, W. Dang, F. B. Johnson, P. D. Adams, D. C. Schultz, S. L. Berger, Histone acetyltransferase p300 induces de novo super-enhancers to drive cellular senescence. *Mol. Cell* **73**, 684–698.e8 (2019).
55. J. Hooda, M. Novak, M. P. Salomon, C. Matsuba, R. I. Ramos, E. MacDuffie, M. Song, M. S. Hirsch, J. Lester, V. Parkash, B. Y. Karlan, M. Oren, D. S. Hoon, R. Drapkin, Early loss of histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. *Cancer Res.* **79**, 760–772 (2019).
56. V. van Duinen, D. Zhu, C. Ramakers, A. J. van Zonneveld, P. Vulto, T. Hankemeier, Perfused 3D angiogenic sprouting in a high-throughput in vitro platform. *Angiogenesis* **22**, 157–165 (2019).
57. D. A. Bader, S. M. Hartig, V. Putluri, C. Foley, M. P. Hamilton, E. A. Smith, P. K. Saha, A. Panigrahi, C. Walker, L. Zong, H. Martini-Stoica, A. Panigrahi, R. Chen, K. Rajapakshe, C. Coarfa, A. Sreekumar, N. Mitsiades, J. A. Bankson, M. M. Ittman, B. M. O'Malley, N. Putluri, S. E. McGuire, Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. *Nat. Metab.* **1**, 70–85 (2019).
58. T. Strub, F. G. Ghiraldini, S. Carcamo, M. Li, A. Wroblewska, R. Singh, M. S. Goldberg, D. Hasson, Z. Wang, S. J. Gallagher, P. Hersey, A. Ma'ayan, G. V. Long, R. A. Scolyer, B. Brown, B. Zheng, B. Bernstein, SIRT6 haploinsufficiency induces BRAF(V600E) melanoma cell resistance to MAPK inhibitors via IGF signalling. *Nat. Commun.* **9**, 3440 (2018).
59. T. Grote, D. R. Siwak, H. A. Fritsche, C. Joy, G. B. Mills, D. Simeone, D. C. Whitcomb, C. D. Logsdon, Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. *Proteomics* **8**, 3051–3060 (2008).

Acknowledgments: We thank K. Doberstein and R. Young for support and critical reading of the manuscript. We appreciate members of the Drapkin laboratory for helpful suggestions and discussions. We are grateful to C. Lopez-Haber for technical insights, G. Dressler for sharing the PAX8-Luciferase reporter vector, and A. Kung for donating the FUW-Luc-mCherry vector. In addition, we are very grateful for the Penn Stem Cell and Xenograft Core, the Penn Quantitative Proteomics Resource Core, and the MD Anderson RPPA Core (NCI P30 CA16672) for technical assistance and resource access. We are also very appreciative of T. Secreto's and L. Schwartz's support and expertise. **Funding:** This work was supported by NIH SPOR in ovarian cancer P50 CA228991 (to R.D.), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (to R.D.), the Honorable Tina Brozman Foundation for Ovarian Cancer Research (to R.D.), the Basser Center for BRCA (to R.D.), the Claneil Foundation (to R.D.), NIH P01CA196539 (to B.A.G.), the Ann and Sol Schreiber Mentored Investigator Award (545754) from the Ovarian Cancer Research Alliance (to D.C.-M.), the Liz Tilberis Early Career Award (599175), also from the Ovarian Cancer Research Alliance (to K.L.), and a Research Scholars Grant from the American Cancer Society (to K.L.). **Author contributions:** D.C.-M. and R.D. conceived the project and the experimental plan. D.C.-M., M.A.M., C.A., P.R., R.N., J.R., R.I.C., L.K.A., I.A.K., S.M., B.W., G.E.K., D.C.B., K.L., P.J.M., and R.D. carried out experiments and analyzed the results. S.S. and B.A.G. performed and analyzed the mass spectrometry data. D.C.-M., P.J.M., and R.D. drafted the manuscript. All authors provided critical commentary and revisions and reviewed the final manuscript. R.D. served as the overall study supervisor. **Competing interests:** G.E.K. has served on speaker bureaus for Clovis Oncology, GSK, and AstraZeneca and received research funding from Lilly and Merck. I.A.K. is now an officer, employee, and shareholder of Dewpoint Therapeutics. R.D. serves on the scientific advisory board of VOC Health and Repare Therapeutics. The other authors declare that they have no competing interest. **Data and materials availability:** The RNA-seq dataset (GSE151316) and the ChIP-seq dataset (GSE152885) have been deposited in GEO. The mass spectrometry raw files are publicly available in the repository Chorus at the project number 1755. All other data needed to evaluate the conclusions in the paper are present in the paper or the Supplementary Materials.

Submitted 3 September 2021

Accepted 16 March 2022

Published 5 April 2022

10.1126/scisignal.abm2496

The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17

Daniele Chaves-MoreiraMarilyn A. MitchellCristina ArruzaPriyanka RawatSimone SidoliRobbin NamekiJessica ReddyRosario I. CoronaLena K. AfeyanIsaac A. KleinSisi MaBoris WinterhoffGottfried E. KonecnyBenjamin A. GarciaDonita C. BradyKate LawrensonPatrice J. MorinRonny Drapkin

Sci. Signal., 15 (728), eabm2496. • DOI: 10.1126/scisignal.abm2496

A PAX8-SOX17 duo in tumor angiogenesis

The transcription factor PAX8 is essential for the development of the female reproductive tract but is frequently amplified in and supports the growth of ovarian cancers. By comparing ovarian cancer and nonmalignant fallopian tube cells and tissues, Chaves-Moreira *et al.* found that PAX8 interacted with another transcription factor, SOX17, and that this complex in cancer cells transcriptionally promoted a proangiogenic secretome, which involved a decrease in plasminogen activator inhibitor 1 and an increase in factors like VEGF. Repressing the complex inhibited tumor cell–induced angiogenesis in both cell culture and in vivo models. The findings may facilitate antiangiogenic strategies for treating ovarian cancer.

View the article online

<https://www.science.org/doi/10.1126/scisignal.abm2496>

Permissions

<https://www.science.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of service](#)